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The costimulatory molecules CD28, cytotoxic T-lymphocyte antigen-4 (CTLA-4) (cytotoxic T-lymphocyte-associated antigen-4)
and inducible costimulator (ICOS) are believed to have a critical modulatory role in the immune response. However, few studies
have been performed on the role of these immune regulatory molecules and their polymorphisms in women with preeclampsia
(PE). The aim of our study was to evaluate the CTLA4 (+49 A/G) (rs 231775), CD28 (+17 T/C) (rs 3116496) and ICOS
(1564 T/C) (rs 4675378) gene polymorphisms in Brazilian women with PE. This case–control study included 130 patients
with PE and 261 control women without any obstetric or systemic disorders. Genomic DNA was extracted from peripheral blood,
and the polymorphism genotyping was performed by digesting the PCR products with the restriction endonucleases BbvI
(CTLA-4), AfeI (CD28) and AluI (ICOS). Data were analyzed by v2 or Fisher’s exact test; a P-value of o0.05 was considered as
significant. There were significant differences in the ICOS genotype and allelic frequencies between the PE and control groups
(P¼0.01 and P¼0.01, respectively). We found a significantly lower frequency of the ICOS (1564) T allele in women with mild
PE compared with the controls. There were no differences in the CTLA-4 (+49 A/G) and CD28 (+17 T/C) genotypes and allelic
frequencies between the PE patients and controls. Our data suggest that PE is associated with ICOS, but is not associated with
the CTLA-4 or CD28 gene polymorphisms.
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INTRODUCTION
Preeclampsia (PE) affects approximately one in every 10 pregnancies
and is an important cause of maternal and perinatal adverse outcomes.
In Latin America, hypertensive disorders are the most common cause of
maternal death.1 Despite its clinical relevance and frequency, the
etiology and pathogenic mechanisms of PE remain unclear, possibly
because PE is a multi-factorial disease with several different risk factors.
Additionally, this condition can present in various clinical forms,
ranging from mild PE occurring late in pregnancy to severe forms
that may present early in the second trimester, which, in fact, could have
different etiopathogenic pathways.2–5
Many investigations suggest that PE is an immune-mediated dis-
order.6,7 However, there is a paucity of studies that involve immuno-
regulatory molecules and their polymorphisms in women with PE.
The expression of the cytotoxic T-lymphocyte antigen-4 (CTLA-4)
molecule on regulatory T cells is considered to be critical for
the maintenance of tolerance at the maternal–fetal interface.8,9
Together with CTLA-4, the costimulatory molecule CD28 and the
inducible costimulator (ICOS) gene are important regulators of the
immune system, and their corresponding genes are located on the
chromosome 2q33.10–12
The single-nucleotide polymorphisms of these T-cell regulatory
genes have been associated with autoimmune diseases13,14 and with
acute allograft rejections after liver transplants.15 According to current
theories, PE can also be considered a type of immune disorder.3,16
Until now, only two studies have analyzed the CTLA-4 gene
polymorphism in women with PE. The first study involved a small
group of Iranian patients17 and suggested that heterozygosis could be
a predisposing factor for severe PE. However, Ja¨a¨skela¨inen et al.18
analyzed the same polymorphism in a Finnish population and
reported that the G allele appeared to be the risk allele for PE.
To the best of our knowledge, there have been no previous studies
assessing the association between PE and the CD28 or ICOS genetic
polymorphisms.
Although the exact mechanisms are not yet completely understood,
there seems to be a clear genetic predisposition to PE,16,19 and
chromosome 2 appears to be implicated in this tendency. Coinciden-
tally, the ICOS, CD28 and CTLA-4 genes are located on this
chromosome.10,11
The aim of our study was to evaluate the CTLA4 (+49 A/G)
(rs 231775), CD28 (+17 T/C) (rs 3116496) and ICOS (-1564 T/C)
(rs 4675378) gene polymorphisms in Brazilian women with PE.
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METHODS
Subjects
This case–control study comprised pregnant women who were referred to the
obstetric ward of the Sao Paulo Hospital (Sao Paulo Federal University) or
admitted to the Dr Ma´rio de Moraes Altenfelder Municipal Teaching Hospital
(both facilities located in Sao Paulo, Brazil) between 2007 and 2009. The study
group included 130 women diagnosed with PE according to the criteria
proposed by the ‘National High Blood Pressure Education Program’.20 Accord-
ing to these recommended guidelines, PE was defined as the presence of systolic
blood pressure X140 mm Hg and diastolic blood pressure X90 mm Hg after
20 weeks of gestation in a previously normotensive woman, accompanied by
proteinuria (urinary excretion ofX0.3 g protein in a 24-h specimen). Women
with blood pressure o160/110 mm Hg (systolic/diastolic), a normal platelet
count, normal liver enzyme values and no maternal symptoms were classified
as having mild PE; all others were classified as cases of severe PE.
The exclusion criteria consisted of the presence of following: a multiple
gestation, fetal death, autoimmune diseases, diabetes, uterine malformation,
in vitro fertilization treatment, placental abruption, infection and cancer or any
other systemic disease, including pre-existing hypertension.
The control group included 261 pregnant women matched by race to the
study group. Control women had to be normotensive during the index
pregnancy and must have had a history of at least two previous normal
pregnancies without any maternal or fetal disorders.
The study protocol was approved by the Ethics Committees of both aforemen-
tioned hospitals, and written informed consent was obtained from all participants.
Upon admission, 10 ml of peripheral blood was collected from each
participant in tubes containing ethylenediamine tetraacetic acid (BD Diagnos-
tics, Franklin Lakes, NJ, USA). The tubes were immediately centrifuged to
obtain the buffy coat layer containing the polymorphonuclear cells, and the
DNA was extracted by the dodecyl trimethyl ammonium bromide/cetyl
trimethyl ammonium bromide method.21
Genotyping of polymorphisms
The sequences of the primers and cycling conditions, as well as the genotyping
methods have been previously described.12 The CTLA-4 (rs231775),
CD28 (rs3116496) and ICOS (rs4675378) gene polymorphisms were genotyped
by the restriction fragment length polymorphism method.12 Briefly, the
CTLA-4, CD28 and ICOS PCR products were digested with the BbvI, AfeI
and AluI restriction endonucleases (New England Biolabs, Beverly, MA, USA),
respectively.
The CTLA-4 gene polymorphism genotyping resulted in fragment sizes of
464 bp (A) or 239 and 255 bp (G). The CD28 gene polymorphism resulted in
sizes of 149 bp (C) or 125 and 24 bp (T). Finally, the ICOS gene polymorphism
genotyping resulted in fragment sizes of 385 bp (T) or 339 and 289 bp (C).
All PCR products were visualized by electrophoresis on an agarose gel that
was stained with ethidium bromide.
Statistical analysis
Two-tailed, pooled Student’s t-tests were used to analyze continuous variables.
The sample size estimates were based on the CTLA4 (+49 A/G) gene
polymorphism (rs 231775) frequency, according to the Hap Map Project
(http://www.hapmap.org/cgi-perl/gbrowse/hapmap27_B36/) data, which defined
an allele risk of 39% in the European Caucasian population. Applying the
allele risk data in the Power and Sample Size Program Version 2.1.3022 and
considering an 80% power and a two-tailed a value of 0.05, a sample size of 108
patients per group was determined to be sufficient to detect an association
between the alleles and PE.
The Hardy–Weinberg equilibrium tests were performed by calculating the
expected frequencies of each genotype and comparing them with the observed
values. The single allelic and single genotype frequencies (obtained by direct
count) were analyzed by the Fisher’s exact or w2-tests, with the level of
significance set at 0.05 and the Bonferroni correction for multiple testing.
The odds ratios and 95% confidence intervals were calculated. A statistical
analysis was performed with standard software (SPSS for the Social Science,
v13.1 for Windows).
RESULTS
The clinical characteristics of participants are presented on Table 1.
All single-nucleotide polymorphisms in the PE and control groups
were in Hardy–Weinberg equilibrium. The genotype and allele fre-
quencies are shown in Table 2. The genotype and allelic frequencies of
the controls and of the patients with mild and severe PE are presented
in Table 3.
There were significant differences in ICOS (1564 T/C) genotype
(TT vs. TC vs. CC—corrected P¼0.03, w2 test) and allelic frequencies
(corrected P¼0.03, w2 test) between PE and controls. We also found a
significantly lower frequency of the T allele in the mild PE patients
compared with the controls (corrected P¼0.03). However, there were
no statistically significant differences in the genotype and allelic
frequencies between the mild and severe PE groups.
There were no differences in the CTLA-4 (+49 A/G) and CD28 (+49
A/G) genotypes and allelic frequencies between the PE patients and
controls. We detected a significant difference in the CTLA4 +49
genotype frequencies between the mild and severe PE groups
(P¼0.03, w2-test), although this was not confirmed after the Bonfer-
roni correction (corrected P¼0.12). Additionally, we did not identify
any association between the CTLA-4 and CD28 gene polymorphisms
when comparing the controls vs. the patients with mild or severe PE.
DISCUSSION
Our results suggest an association between the ICOS gene polymorph-
ism and PE. However, we did not detect any relationship between the
CTLA-4 and CD28 gene polymorphisms and PE.
The genotype frequencies were in Hardy–Weinberg equilibrium in
both the patients and controls. Bearing in mind the importance of
ethnical matching in disease association studies, our groups were
matched by race.23–26 In addition, the genotype frequencies were
similar to those previously reported for the Brazilian population.12
Most association studies between pregnancy and immunoregula-
tory molecules have focused mainly on CTLA-4.17,18,27 The T regula-
tory (Treg) cells that express the activation marker CTLA-4 are critical
for the maintenance of maternal tolerance to fetal antigens.8,9 Addi-
tionally, a decreased ratio of CTLA-4(+)/CD28(+) expression, both in
peripheral blood and in deciduas, seems to be associated with
pregnancy loss.28 Several studies have shown that ICOS has a pivotal
role in T-cell activation and in Th1/Th2 differentiation.29 Despite this,
the role of ICOS has not been previously investigated in pregnancy, a
condition that is clearly influenced by these processes. To the best of
our knowledge, this is the first study to simultaneously evaluate these
three immunoregulatory molecule gene polymorphisms in pregnancy.
We observed a significantly lower frequency of the ICOS 1564 T
allele and of the TT genotype in the women with PE compared with
Table 1 Characteristics of women included in the study
Variable Preeclampsia n¼130 Control n¼261 P-value
Agea 25.79±6.85 30.72±9.29 o0.0001
Number of pregnanciesa 1.9±1.49 2.51±1.38 0.0003
Raceb
White 73 (56%) 174 (67%) 0.09
Mulatto 36 (28%) 60 (23%)
Black 21 (16%) 27 (10%)
Gestational age at collectiona 33.18±4.98 31.93±5.05 0.14
aData presented as mean±s.e.m. and analyzed by Student’s t-test.
bData analyzed by w2-test.
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the controls. Similar results were reported in patients with type 1
diabetes.30 In a study involving Finnish and Estonian participants,
Douroudis et al.30 detected a marginally significant decrease in
frequency of the CTIC154_1 T allele in the group of type 1 diabetics.
Thus, this gene polymorphism might be related to the immune/
inflammation processes. Although little is known about the functional
role of this polymorphism, other investigators have reported that
variations in noncoding regions may influence the mRNA of the ICOS
gene and subsequently affect its expression.29,31
Ja¨a¨skela¨inen et al.18 did not detect an association between the
CTLA-4 +49 genotype and PE, but did detect an increased frequency
of the G allele in Finnish PE patients. In contrast, an increased frequency
of the GA genotype was reported among Iranian women with severe
PE.17 Our data also showed an increased frequency of the GA genotype
in Brazilian women with severe PE; however, this difference was not
confirmed after the Bonferroni correction. These controversial findings
could be attributed to the sample size, statistical analysis and differences
in the polymorphism distribution among races.
The CTLA-4 expression seems to be critical for the suppressive
effects of Treg cells.32 Although none of the three studies evaluated the
expression of this molecule, differences in this polymorphism seem to
modify the CTLA-4 expression and compromise the activity of the
Treg cells.8,33,34
Further studies are needed to validate the biological significance of
the ICOS (1564 T/C) gene polymorphism identified in the present
study. Although the number of participants was not large, ours is the
first study to investigate the association between PE and this specific
genetic marker. These results need to be replicated in larger groups of
women and in more ethnically diverse populations.
The genes of the costimulatory molecules CD28, CTLA-4 and
ICOS are situated in the same region on chromosome 2q33.11,12,31
As previously reported by other investigators, this chromosome seems
to be implicated in a woman’s predisposition to PE.10 In addition to
being located closely together on the same chromosome, these three
molecules seem to be implicated in the Th1—Th2 balance through
Treg activation.8,29 Previous studies have reported that women with
PE have altered Treg cell numbers and/or function.8,35 Due to these
common characteristics, we can speculate that these three genes could
be involved in the susceptibility to the same disease. On the basis of
this assumption, we investigated the possible existence of associations
between different combinations of these three genetic polymorphisms
and PE but detected none (data not shown).
The role of the genes of these costimulatory molecules needs to be
further investigated in healthy pregnant women and in those with PE.
Specifically, studies assessing the expression of these molecules need to
be conducted, including investigations on the relationship between
maternal and fetal genotype interactions.
In conclusion, our data suggest an association between PE and the
ICOS gene polymorphism, but do not suggest an association between
PE and the CD28 and CTLA-4 gene polymorphisms.
Table 2 Genotype and allele frequencies of CTLA-4, CD28 and ICOS gene polymorphisms in women with preeclampsia and controls
Preeclampsia Control OR (95% CI) P-value Corrected P-valuea
CTLA-4 (+49)
Genotypesb n¼125 n¼158
AA 58 (46.4%) 76 (48.1%) 0.62 —
AG 47 (37.6%) 63 (39.9%)
GG 20 (16%) 19 (12%)
GG(AG+AA)c 1.39 (0.70–2.74) 0.38 —
Allelesc n¼250 n¼316
A 163 (65.2%) 215 (68%) 1.13 (0.79–1.61) 0.52 —
G 87 (34.8%) 101 (32%)
CD28 (+17)
Genotypesb n¼125 n¼171
TT 84 (67.2%) 125 (73.1%) 0.38 —
TC 34 (27.2%) 41 (24%)
CC 7 (5.6%) 5 (2.9%)
TT(TC+CC)c 0.63 (0.38–1.06) 0.08 —
Allelesc n¼250 n¼342
T 202 (80.8%) 291 (85.1%) 0.73 (0.47–1.13) 0.18 —
C 48 (19.2%) 51 (14.9%)
ICOS (1564)
Genotypesb n¼124 n¼167
TT 52 (41.9%) 99 (59.3%) 0.01 0.03
TC 60 (48.4%) 54 (32.3%)
CC 12 (9.7%) 14 (8.4%)
TT(TC+CC)c 0.49 (0.30–0.79) 0.004 0.012
Allelesc n¼248 n¼334
T 164 (66.1%) 252 (75.4%) 0.63 (0.44–0.91) 0.01 0.03
C 84 (33.9%) 82 (24.6%)
Abbreviations: CI, confidence interval; OR, odds ratio.
aBonferroni correction.
bw2-test.
cFischer’s exact test.
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